Medinice

Medinice EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Medinice (ICE.WA) as of Oct 22, 2026 is -7.31 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 42.99 % — a change of -117.00% (lower).

EBIT/Assets

-7.31 %

YoY

-117.00%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Medinice is 2025 -7.31 % . Operating Income to Assets Ratio (EBIT/Assets) of Medinice was 2024 42.99 % . It decreases by -117.00% lower compared to the previous year.

The Medinice EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-22.94 PLN
Jan 1, 2019
-17.24 PLN
Jan 1, 2020
-13.75 PLN
Jan 1, 2021
-7.12 PLN
Jan 1, 2022
-11.93 PLN
Jan 1, 2023
-15.41 PLN
Jan 1, 2024
42.99 PLN
Jan 1, 2025
-7.31 PLN
The Medinice EBIT/Assets history
YEAREBIT/AssetsYoY
-7.31 %-117.00%
42.99 %-378.93%
-15.41 %+29.19%
-11.93 %+67.64%
-7.12 %-48.23%
-13.75 %-20.25%
-17.24 %-24.86%
-22.94 %+81.98%
-12.61 %-39.50%
-20.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinice Stock analysis

What does Medinice do? Medinice SA generates revenue through the commercialization of medical device solutions, primarily focusing on cardiological and cardiosurgical products. The company's portfolio includes CathAIO, Cryoapplicator, Med-IConsole, Minimax, and Pacepress, which are sold globally via licensing agreements. These products target healthcare providers and medical device manufacturers seeking minimally invasive cardiology solutions. The firm collaborates with research centers in Poland and Europe to develop and commercialize inventions from its co-founders and acquired projects, emphasizing safe and minimally invasive medical technologies. Medinice SA's business model revolves around licensing its proprietary technologies to international partners for the production of medical devices. The company leverages its global potential projects to secure worldwide distribution agreements, ensuring revenue streams from multiple markets. By specializing in cardiology and cardio surgery, Medinice SA positions itself as a provider of innovative solutions for healthcare systems seeking advanced, minimally invasive procedures. The firm's revenue is derived from licensing fees and sales of its medical device solutions, with a focus on cardiological and cardiosurgical applications. Its products, such as CathAIO and Cryoapplicator, are designed to meet global demand for safe and minimally invasive treatments. Medinice SA's strategy involves partnering with research centers in Poland and Europe to enhance its portfolio, ensuring continuous innovation and market relevance in the medical device sector. Medinice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinice stock

Operating Income to Assets Ratio (EBIT/Assets) of Medinice is -7.31 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Medinice changed from 42.99 % to -7.31 %, representing a -117.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Medinice since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Medinice with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medinice

All Key Metrics — Medinice